The Ministry of Health and Family Welfare, Government of India, has issued a Draft Notification (G.S.R. 97(E)) dated 2 February 2026, proposing amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019. The draft focuses on strengthening the regulatory framework for submission and management of post-approval changes in drug manufacturing and quality parameters.
The proposed amendments introduce new provisions under Rule 77 and Rule 82 of the NDCT Rules, 2019, applicable to manufacturers of new drugs and investigational products. The intent is to ensure that any post-approval change that may affect the quality, safety, or efficacy of a drug product is appropriately assessed and communicated to the licensing authority.
Scope of Post-Approval Changes
As per the draft rules, manufacturers or their authorized agents must inform the licensing authority in writing about any changes related to:
- Manufacturing process
- Excipients
- Packaging
- Shelf life
- Specifications
- Testing methods
- Documentation
These requirements apply to both approved new drugs and clinical trial–related products, ensuring regulatory oversight throughout the product lifecycle.
Classification of Quality Changes
A key feature of the draft notification is the risk-based classification of post-approval changes into three levels:
Level I – Major Quality Changes
These changes have a substantial potential to adversely impact the identity, strength, quality, purity, or potency of a drug product. In such cases, prior approval from the licensing authority is mandatory before implementation.
Level II – Moderate Quality Changes
Changes with a moderate potential impact also require prior approval from the licensing authority before being implemented.
Level III – Minor Quality Changes
Minor changes with minimal potential impact may be implemented without prior approval, except for changes related to the shelf life of the drug substance or drug product. However, these changes must be reported through an annual submission.
Get Free Consultation!
Annual Submission Requirement
For Level III changes, manufacturers are required to submit a consolidated annual report to the licensing authority. This submission must be made by the first quarter of every calendar year, ensuring transparency while reducing unnecessary regulatory burden for low-risk changes.
Regulatory Impact and Industry Implications
The proposed amendments align India’s regulatory practices with internationally accepted change management principles, emphasizing risk-based decision-making and product lifecycle management. For pharmaceutical companies, this means greater clarity on compliance expectations, improved planning for post-approval modifications, and enhanced accountability.
Public Consultation
The draft rules have been published for public consultation, and objections or suggestions may be submitted within 30 days from the date of publication in the Gazette of India. Stakeholders can send their feedback to the Ministry of Health and Family Welfare via email or official correspondence.
Conclusion
Once finalized, these amendments are expected to bring greater regulatory clarity and consistency in handling post-approval changes under the NDCT framework. Pharmaceutical manufacturers should proactively review their internal change management systems to ensure alignment with the proposed requirements.